Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

The findings were published in Science Immunology. “Relapse of AML after stem cell transplant is a major challenge,” says first author Katie Maurer, MD, PhD. “There are few effective ...

The outcomes of treatment with gemtuzumab ozogamicin compared with those of conventional chemotherapy for relapse of acute myelogenous leukemia (AML) were studied. The gemtuzumab ozogamicin group ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

The median age at the time of transplantation was 8.9 years ... molecular characterization," for children with relapsed and refractory AML who are not enrolled in clinical trials.